These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
232 related items for PubMed ID: 1776864
1. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Chen G, Zeller WJ. Anticancer Res; 1991; 11(6):2231-7. PubMed ID: 1776864 [Abstract] [Full Text] [Related]
2. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067. Xu BH, Singh SV. Cancer Res; 1992 Dec 01; 52(23):6666-70. PubMed ID: 1423311 [Abstract] [Full Text] [Related]
3. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine. Kramer RA, Greene K, Ahmad S, Vistica DT. Cancer Res; 1987 Mar 15; 47(6):1593-7. PubMed ID: 3815359 [Abstract] [Full Text] [Related]
4. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin. Chen G, Zeller WJ. Anticancer Res; 1993 Mar 15; 13(1):219-23. PubMed ID: 8476216 [Abstract] [Full Text] [Related]
5. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Lai SL, Hwang J, Perng RP, Whang-Peng J. Oncol Res; 1995 Mar 15; 7(1):31-8. PubMed ID: 7549042 [Abstract] [Full Text] [Related]
6. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM. Clin Cancer Res; 1996 Dec 15; 2(12):1961-8. PubMed ID: 9816155 [Abstract] [Full Text] [Related]
7. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow. Ono K, Shrieve DC. J Natl Cancer Inst; 1987 Oct 15; 79(4):811-5. PubMed ID: 3477662 [Abstract] [Full Text] [Related]
8. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Frühauf S, Zeller WJ. Cancer Res; 1991 Jun 01; 51(11):2943-8. PubMed ID: 2032232 [Abstract] [Full Text] [Related]
9. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. Ali-Osman F, Antoun G, Wang H, Rajagopal S, Gagucas E. Mol Pharmacol; 1996 Jun 01; 49(6):1012-20. PubMed ID: 8649339 [Abstract] [Full Text] [Related]
10. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin. Chen G, Zeller WJ, Todorov DK. Anticancer Res; 1993 Jun 01; 13(5A):1269-75. PubMed ID: 8239496 [Abstract] [Full Text] [Related]
11. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells. Kisara S, Furusawa S, Murata R, Ogata M, Hikichi N, Takayanagi Y, Sasaki K. Oncol Res; 1995 Jun 01; 7(3-4):191-200. PubMed ID: 8555653 [Abstract] [Full Text] [Related]
12. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC. Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674 [Abstract] [Full Text] [Related]
13. Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Andrews PA, Murphy MP, Howell SB. Cancer Res; 1985 Dec 01; 45(12 Pt 1):6250-3. PubMed ID: 4063975 [Abstract] [Full Text] [Related]
14. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Peters RH, Jollow DJ, Stuart RK. Cancer Res; 1991 May 15; 51(10):2536-41. PubMed ID: 2021933 [Abstract] [Full Text] [Related]
15. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice. Soble MJ, Dorr RT. Anticancer Res; 1988 May 15; 8(1):17-22. PubMed ID: 3358633 [Abstract] [Full Text] [Related]
16. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Shellard SA, Hosking LK, Hill BT. Cancer Res; 1991 Sep 01; 51(17):4557-64. PubMed ID: 1873800 [Abstract] [Full Text] [Related]
17. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells. Hansson J, Edgren M, Ehrsson H, Ringborg U, Nilsson B. Cancer Res; 1988 Jan 01; 48(1):19-26. PubMed ID: 3334994 [Abstract] [Full Text] [Related]
18. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Xu BH, Gupta V, Singh SV. Arch Biochem Biophys; 1994 Jan 01; 308(1):164-70. PubMed ID: 8311448 [Abstract] [Full Text] [Related]
19. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery. Bertsche U, Schorn H. Radiat Res; 1986 Mar 01; 105(3):351-69. PubMed ID: 3754339 [Abstract] [Full Text] [Related]
20. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Mistry P, Loh SY, Kelland LR, Harrap KR. Int J Cancer; 1993 Nov 11; 55(5):848-56. PubMed ID: 8244583 [Abstract] [Full Text] [Related] Page: [Next] [New Search]